CHEK1 and cancer: Given that dysregulation of the cell cycle is a hallmark of cancer,50 the pathway involving FBXO7, P27, and CHEK1 may represent an exploitable therapeutic target, particularly for cancers exhibiting FBXO7 copy number losses.